Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics Corporation, originally Amur Minerals, announced positive interim results following its AIM admission and Reverse Takeover, highlighting the development of ChemoSeed®, an innovative drug delivery technology for chemotherapy. The company is preparing for a Phase 2 clinical trial for high-grade glioma, with significant backing including an MHRA Innovation Passport and financial support from SPARK the Midlands. CRISM has also gained additional revenue through a service agreement with imphatec and is optimistic about the future application of ChemoSeed for various cancers.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
